JP2016537364A5 - - Google Patents

Download PDF

Info

Publication number
JP2016537364A5
JP2016537364A5 JP2016530937A JP2016530937A JP2016537364A5 JP 2016537364 A5 JP2016537364 A5 JP 2016537364A5 JP 2016530937 A JP2016530937 A JP 2016530937A JP 2016530937 A JP2016530937 A JP 2016530937A JP 2016537364 A5 JP2016537364 A5 JP 2016537364A5
Authority
JP
Japan
Prior art keywords
laquinimod
day
pharmaceutical composition
formulated
package
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016530937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537364A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065497 external-priority patent/WO2015073697A1/en
Publication of JP2016537364A publication Critical patent/JP2016537364A/ja
Publication of JP2016537364A5 publication Critical patent/JP2016537364A5/ja
Withdrawn legal-status Critical Current

Links

JP2016530937A 2013-11-15 2014-11-13 ラキニモドを用いた緑内障の治療 Withdrawn JP2016537364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904962P 2013-11-15 2013-11-15
US61/904,962 2013-11-15
PCT/US2014/065497 WO2015073697A1 (en) 2013-11-15 2014-11-13 Treatment of glaucoma using laquinimod

Publications (2)

Publication Number Publication Date
JP2016537364A JP2016537364A (ja) 2016-12-01
JP2016537364A5 true JP2016537364A5 (enExample) 2017-12-28

Family

ID=53058023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530937A Withdrawn JP2016537364A (ja) 2013-11-15 2014-11-13 ラキニモドを用いた緑内障の治療

Country Status (12)

Country Link
US (6) US20150141458A1 (enExample)
EP (1) EP3068395A4 (enExample)
JP (1) JP2016537364A (enExample)
KR (1) KR20160100302A (enExample)
CN (1) CN105960238A (enExample)
AU (1) AU2014348620A1 (enExample)
CA (1) CA2930113A1 (enExample)
EA (1) EA201690903A1 (enExample)
HK (1) HK1225971A1 (enExample)
IL (1) IL245373A0 (enExample)
MX (1) MX2016006256A (enExample)
WO (1) WO2015073697A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019182814A (ja) * 2018-04-17 2019-10-24 国立大学法人九州大学 生体リズム調整剤及び生体リズム調整用医薬組成物
EP3886858B1 (en) * 2019-12-19 2022-05-11 Active Biotech AB Compounds for treatment of eye diseases associated with excessive vascularisation
EP3888650A1 (en) * 2020-03-30 2021-10-06 Universität Regensburg Biochanin a diacetate for treatment of best1-related retinopathies
MX2023010971A (es) 2021-04-01 2023-09-27 Active Biotech Ab Formulacion de laquinimod para uso ocular.
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US8039507B2 (en) * 2005-06-29 2011-10-18 Allergan, Inc. Therapeutic substituted gamma lactams
EP2318371A2 (en) * 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
AU2010276748A1 (en) * 2009-07-30 2012-03-15 Teva Pharmaceutical Industries Ltd. Treatment of Crohn's disease with laquinimod
HUE029983T2 (en) * 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
CN103781354A (zh) * 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
CN103561744A (zh) 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮在治疗免疫相关性和炎症性疾病中的用途
WO2012079092A3 (en) Testosterone undecanoate compositions
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2014528474A5 (enExample)
JP2016537364A5 (enExample)
JP2005523316A5 (enExample)
NZ784949A (en) Ripretinib for treating gastrointestinal stromal tumors
NZ604029A (en) Methods of treating bladder cancer
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
JP2012520866A5 (enExample)
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2013513612A5 (enExample)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ714963A (en) Compositions and methods for treating anemia
JP2019507758A5 (enExample)
JP2013518051A5 (enExample)
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
RU2013137645A (ru) Аналоги цистамина, применяемые для лечения болезни паркинсона
JP2020500864A5 (enExample)
JP2019514990A5 (enExample)
JP2015522077A5 (enExample)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2016505050A5 (enExample)